Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 6, 2010, Pages 1399-1408

  Santosh, Vani ^a   Arivazhagan, Arimappamagan ^a   Sreekanthreddy, Peddagangannagari ^b   Srinivasan, Harish ^b   Thota, Balaram ^a   Srividya, Mallavarapu R ^a   Vrinda, Marigowda ^a   Sridevi, Sambandam ^b   Shailaja, Bangalore C ^a   Samuel, Cini ^c   Prasanna, Krishnarao V ^c   Thennarasu, Kandavel ^a   Balasubramaniam, Anandh ^a   Chandramouli, Bangalore A ^a   Hegde, Alangar S ^c   Somasundaram, Kumaravel ^b   Kondaiah, Paturu ^b   Rao, Manchanahalli R S ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

^d JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; IGFBP3 PROTEIN, HUMAN; SOMATOMEDIN BINDING PROTEIN;

ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CORRELATION ANALYSIS; FOLLOW UP; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; ADULT; BIOSYNTHESIS; BRAIN TUMOR; COHORT ANALYSIS; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; PROSPECTIVE STUDY; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; COHORT STUDIES; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77953316513     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-1213     Document Type: Article

References (39)

1. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25.
2. Kleihues P, Louis DN, Wiestler OD, Burger PC, Schiethauer BW. WHO grading of tumors of central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumors of the central nervous system. 4th ed. Lyon (France): IARC Press; 2007, p. 10-11.
3. Palanichamy K, Erkkinen M, Chakravarti A. Predictive and prognostic markers in human glioblastomas. Curr Treat Options Oncol 2006;7:490-504. (Pubitemid 44697786)
4. Ho DM, Hsu CY, Ting LT, Chiang H. MIB-1 and DNA topoisomerase IIα could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol 2003;119:715-22.
5. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008;9:29-38.
6. Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009;18:1061-83.
7. Wang H, Fuller GN, Zhang W. Insulin-like growth factors and insulin-like growth factors binding proteins in CNS tumors. In: Zhang W, Fuller GN, editors. Genomic and molecular neuro-oncology. Sudbury: Jones and Bartlett Publishers; 2004, p. 119-30.
8. Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD. Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 2007;145:795-811. (Pubitemid 46441671)
9. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006;13:S33-43.
10. Hirano H, Lopes MB, Laws ER, Jr., et al. Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro-oncol 1999;1:109-19.
11. Zumkeller W, Westphal M. The IGF/IGFBP system in CNS malignancy. Mol Pathol 2001;54:227-9.
12. Fuller GN, Rhee CH, Hess KR, et al. Reactivation of insulin-like growth factor binding protein 2 expression in GBM multiforme: a revelation by parallel gene expression profiling. Cancer Res 1999;59:4228-32.
13. Wang H, Wang H, Zhang W, Fuller GN. Tissue micro arrays: applications in neuropathology research, diagnosis and education. Brain Pathol 2002;12:95-107. (Pubitemid 33131366)
14. Elmlinger MW, Deininger MH, Schuett BS, et al. In vivo expression of insulin-like growth factor-binding protein-2 in human glioma increases with the tumor grade. Endocrinology 2001;142:1652-8.
15. Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000;60:6617-22.
16. Wang H, Wang H, Shen W, et al. Insulin-like growth factor binding protein 2 enhances GBM invasion by activating invasion-enhancing genes. Cancer Res 2003;63:4315-21.
17. McDonald KL, O'Sullivan MG, Parkinson JF, et al. IQGAP1 and IGFBP-2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 2007;66:405-17.
18. Lin Y, Jiang T, Zhou K, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro-oncol 2009;11:468-76.
19. Wang H, Wang H, Zhang W, Fuller GN. Over expression of IGFBP5, but not IGFBP3, correlates with the histologic grade of human diffuse glioma: a tissue microarray and immunohistochemical study. Technol Cancer Res Treat 2006;5:195-200.
20. Reddy SP, Britto R, Vinnakota K, et al. Novel GBM markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res 2008;14:2978-87.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
22. Somasundaram K, Reddy SP, Vinnakota K, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 2005;24:7073-83.
23. Vincent AM, Feldman EL. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 2002;12:193-7.
24. Song SW, Fuller GN, Khan A, et al. IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc Natl Acad Sci U S A 2003;100:13970-5.
25. Ragel BT, Couldwell WT, Gillespie DL, Jensen RL. Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis. Neurosurg Rev 2007;30:181-7.
26. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
27. Marucci G, Morandi L, Magrini E, et al. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 2008;453:599-609.
28. Dunlap SM, Celestino J, Wang H, et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A 2007;104:11736-41.
29. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes 1,2. Cancer Res 2003;63:6613-25.
30. Beilharz EJ, Russo VC, Butler G, et al. Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury. Brain Res Mol Brain Res 1998;59:119-34.
31. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
32. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001;54:145-8.
33. Ruano Y, Mollejo M, Camacho FI, et al. Identification of survival-related genes of the phosphatidylinositol 30-kinase signaling pathway in GBM multiforme. Cancer 2008;112:1575-84.
34. Vestey SB, Perks CM, Sen C, Calder CJ, Holly JM, Winters ZE. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. Breast Cancer Res 2005;7:R119-29.
35. Jiang R, Mircean C, Shmulevich I, et al. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 2006;6:2964-71.
36. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
37. Martin JL, Weenink SM, Baxter RC. Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases. J Biol Chem 2003;278:2969-76.
38. Akkiprik M, Hu L, Sahin A, Hao X, Zhang W. The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer. BMC Cancer 2009;9:103.
39. Wang H, Arun BK, Wang H, et al. IGFBP2 and IGFBP5 over expression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 2008;14:261-7.